Skip to main content
. Author manuscript; available in PMC: 2011 May 27.
Published in final edited form as: Biol Blood Marrow Transplant. 2009 Oct;15(10):1143–1238. doi: 10.1016/j.bbmt.2009.06.019

Pathogen: Strongyloides species

Indication First choice Alternatives
Prevention of strongyloidiasis hyperinfection among HCT candidates who demonstrate:

  1. positive screening tests for Strongyloides species (BIII); or

  2. unexplained eosinophilia and a travel or residence history suggestive of exposure to Strongyloides stercoralis (BIII)

Note: Administer prophylaxis before HCT		 Ivermectin 200 μg/kg/day orally daily for 2 consecutive days; repeat after 2 weeks (BIII) [513,839]
Dosing by Weight:
Body
weight (kg) Oral dose
< 15 Not recommended
≥ 15–24 3 mg
25–35 6 mg
36–50 9 mg
51–65 12 mg
66–79 15 mg
≥ 80 200 μg/kg		 Adults/Adolescents
Albendazole: 400 mg orally twice daily for 7 days; or Thiabendazole:
25 mg/kg (maximum 3 gm/day) orally 2 times/day for 2 days (BIII)
Pediatrics
Albendazole 400 mg po twice a day for 7 days; or Thiabendazole:
25 mg/kg (maximum 3 gm/day) orally 2 times/day for 2 days (BIII)

HCT indicates hematopoietic cell transplant.

Notes: Among immunocompromised patients, multiple courses at 2-week intervals might be required; however, cure might not be achievable.

Safety and efficacy of ivermectin has not been established during pregnancy.

Albendazole and thiabendazole are contraindicated during pregnancy.